The pharmaceutical lobby is requiring member companies to fork over an additional $100 million per year as the industry gears up for a bruising post-election battle over drug prices, POLITICO has learned.
PhRMA's decision to hike membership dues 50 percent will increase the trade group's considerable coffers to more than $300 million per year — a financial advantage it hasn't enjoyed since 2009, when drug makers came out largely unscathed in Obamacare negotiations. PhRMA is bolstering its war chest as it gears up to spend hundreds of millions on ads pushing back against politicians from both parties who have attacked its members over pricing.
